Datopotamab Deruxtecan Receives FDA Approval as Breast Cancer Treatment
Datopotamab deruxtecan (Dato-DXd) is now an FDA-approved treatment for patients with hormone receptor-positive, HER2-negative breast cancer. The approval is supported by data from the phase 3 TROPION-Breast01 trial, which showed that Dato-DXd demonstrated better progression-free survival and overall response rates compared to chemotherapy. In the trial, Dato-DXd was found to have a median progression-free survival … Read more